Shevanthi Nayagam
Overview
Explore the profile of Shevanthi Nayagam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1748
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Villiers M, de Villiers E, Nayagam S, Hallett T
Epidemics
. 2024 Nov;
49:100798.
PMID: 39541625
Population-level vaccination effects of the hepatitis B vaccine were investigated in four low- and middle-income countries with different levels of vertical and horizontal transmission. Indirect vaccination effects constitute a large...
2.
Delamare H, Ishii-Rousseau J, Rao A, Cresta M, Vincent J, Segeral O, et al.
JHEP Rep
. 2024 Jul;
6(8):101064.
PMID: 39035070
Background & Aims: In 2020, the World Health Organization (WHO) recommended peripartum antiviral prophylaxis (PAP) for pregnant women infected with hepatitis B virus (HBV) with high viremia (≥200,000 IU/ml). Hepatitis...
3.
Luong Nguyen L, Lemoine M, Ndow G, Nayagam S, Shimakawa Y
Lancet Glob Health
. 2024 May;
12(6):e917.
PMID: 38762294
No abstract available.
4.
Hartner A, Li X, Echeverria-Londono S, Roth J, Abbas K, Auzenbergs M, et al.
Lancet Glob Health
. 2024 Mar;
12(4):e563-e571.
PMID: 38485425
Background: There have been declines in global immunisation coverage due to the COVID-19 pandemic. Recovery has begun but is geographically variable. This disruption has led to under-immunised cohorts and interrupted...
5.
Nguyen L, Lemoine M, Ndow G, Ward Z, Hallet T, DAlessandro U, et al.
Lancet Glob Health
. 2023 Dec;
12(1):e66-e78.
PMID: 38097300
Background: Global elimination of hepatitis B virus (HBV) requires expanded uptake of antiviral therapy, potentially by simplifying testing algorithms, especially in resource-limited countries. We evaluated the effectiveness, cost-effectiveness, and budget...
6.
Nayagam S, de Villiers M, Shimakawa Y, Lemoine M, Thursz M, Walsh N, et al.
Lancet Gastroenterol Hepatol
. 2023 May;
8(7):635-645.
PMID: 37150181
Background: In 2020, WHO recommended the addition of peripartum antiviral prophylaxis (PAP) to hepatitis B birth dose vaccination (HepB-BD) and hepatitis B infant vaccination (HepB3) to reduce mother-to-child transmission of...
7.
Ansari A, Vincent J, Moorhouse L, Shimakawa Y, Nayagam S
Lancet Glob Health
. 2023 Apr;
11(5):e715-e728.
PMID: 37061310
Background: Sub-Saharan Africa is highly endemic for hepatitis B virus (HBV); historically, most people were exposed during childhood through vertical or horizontal transmission. Although all African countries now provide a...
8.
Cui F, Blach S, Mingiedi C, Gonzalez M, Alaama A, Mozalevskis A, et al.
Lancet Gastroenterol Hepatol
. 2023 Feb;
8(4):332-342.
PMID: 36764320
Background: The 69th World Health Assembly endorsed the global health sector strategy on viral hepatitis to eliminate viral hepatitis as a public health threat by 2030. Achieving and measuring the...
9.
Schmit N, Nayagam S, Lemoine M, Ndow G, Shimakawa Y, Thursz M, et al.
J Glob Health
. 2023 Jan;
13:04004.
PMID: 36655869
Background: Clinical management of chronic hepatitis B virus (HBV) infection is complex and access to antiviral treatment remains limited in sub-Saharan Africa. International guidelines recommend monitoring at least annually for...
10.
Rao A, Moorhouse L, Maswera R, Dadirai T, Mandizvidza P, Nyamukapa C, et al.
PLoS One
. 2022 Sep;
17(9):e0273776.
PMID: 36149912
Background: Manicaland province in eastern Zimbabwe has a high incidence of HIV. Completion of the seventh round of the Manicaland Survey in 2018-2019 provided the opportunity to assess the state...